Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SPARTALIZUMAB: 288 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
288
Total FAERS Reports
23 (8.0%)
Deaths Reported
235
Hospitalizations
288
As Primary/Secondary Suspect
24
Life-Threatening
7
Disabilities

First Report: 20170120 · Latest Report: 20230305

What Are the Most Common SPARTALIZUMAB Side Effects?

#1 Most Reported
Pyrexia
29 reports (10.1%)
#2 Most Reported
Vomiting
17 reports (5.9%)
#3 Most Reported
Diarrhoea
17 reports (5.9%)

All SPARTALIZUMAB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Pyrexia 29 10.1% 1 28
Diarrhoea 17 5.9% 2 15
Vomiting 17 5.9% 3 17
General physical health deterioration 14 4.9% 4 12
Colitis 12 4.2% 1 8
Dyspnoea 12 4.2% 1 10
Febrile neutropenia 12 4.2% 0 12
Pneumonitis 12 4.2% 1 12
Acute kidney injury 11 3.8% 1 11
Nausea 10 3.5% 2 9
Pneumonia 9 3.1% 2 9
Urinary tract infection 9 3.1% 0 9
Neutropenia 8 2.8% 0 8
Thrombocytopenia 8 2.8% 0 8
Abdominal pain 7 2.4% 2 5
Anaemia 7 2.4% 3 7
Disease progression 7 2.4% 4 5
Fatigue 7 2.4% 2 6
Immune-mediated hepatitis 7 2.4% 1 6
Infusion related reaction 7 2.4% 0 7

Who Reports SPARTALIZUMAB Side Effects? Age & Gender Data

Gender: 59.2% female, 40.8% male. Average age: 61.1 years. Most reports from: US. View detailed demographics →

Is SPARTALIZUMAB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2017 17 1 17
2018 94 2 81
2019 60 3 51
2020 35 1 32
2021 31 4 26
2022 21 6 15
2023 12 2 12

View full timeline →

What Is SPARTALIZUMAB Used For?

IndicationReports
Metastatic malignant melanoma 70
Malignant melanoma 67
Non-small cell lung cancer 24
Triple negative breast cancer 19
Pancreatic carcinoma metastatic 18
Neoplasm malignant 12
Ductal adenocarcinoma of pancreas 9
Pancreatic carcinoma 8
Gastric cancer 7
Non-small cell lung cancer metastatic 7

SPARTALIZUMAB vs Alternatives: Which Is Safer?

SPARTALIZUMAB vs SPIRIVA SPARTALIZUMAB vs SPIRONOLACTONE SPARTALIZUMAB vs SPRYCEL SPARTALIZUMAB vs STIVARGA SPARTALIZUMAB vs STREPTOZOCIN SPARTALIZUMAB vs SUCCINYLCHOLINE SPARTALIZUMAB vs SUFENTANIL SPARTALIZUMAB vs SULFAMETHOXAZOLE\TRIMETHOPRIM SPARTALIZUMAB vs SULFASALAZINE SPARTALIZUMAB vs SUMATRIPTAN

Official FDA Label for SPARTALIZUMAB

Official prescribing information from the FDA-approved drug label.